VERSANT HCV Genotype 2.0 Assay (LiPA)

Assay, Genotyping, Hepatitis C Virus

FDA Premarket Approval P160016 S001

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for a modification to the assay procedure to allow the versant kpcr molecular system sample preparation module to automatically set up the pcr plate following the rna extraction step.

DeviceVERSANT HCV Genotype 2.0 Assay (LiPA)
Classification NameAssay, Genotyping, Hepatitis C Virus
Generic NameAssay, Genotyping, Hepatitis C Virus
ApplicantSIEMENS HEALTHCARE DIAGNOSTICS, INC.
Date Received2018-01-02
Decision Date2018-02-08
PMAP160016
SupplementS001
Product CodeOBF
Advisory CommitteeMicrobiology
Supplement TypeReal-time Process
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address SIEMENS HEALTHCARE DIAGNOSTICS, INC. p.o. Box 2466 berkeley, CA 94702-2466

Supplemental Filings

Supplement NumberDateSupplement Type
P160016Original Filing
S006 2020-07-31 30-day Notice
S005
S004 2019-07-25 30-day Notice
S003 2019-03-08 30-day Notice
S002
S001 2018-01-02 Real-time Process

NIH GUDID Devices

Device IDPMASupp
00630414602882 P160016 000
00630414602875 P160016 000
00630414000534 P160016 000
00630414000510 P160016 000
00630414000503 P160016 000
00630414000497 P160016 000

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.